Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology

The early in-hospital introduction of SGLT2i reduced the occurrence of the composite CV death/HFH, all-cause death, CV death and HFH in patients with ischemic cardiomyopathy. In the subgroup analysis of patients admitted due to ACS, the introduction of SGLT2i during the index hospitalization resulted in a significant reduction of the composite CV death/HFH, CV death and all-cause death, but not in HFH. The same therapeutic strategy resulted in reduced rate of CV death/HFH in the de novo HF subpopulation.

Authors

Institutions

Publication Details

Journal
Cardiovascular Drugs and Therapy
Published
2025-05-15
DOI
https://doi.org/10.1007/s10557-025-07714-0
Citations
2
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology

Domenico Filomena, Roberto Badagliacca, Rosanna Germanò, Vincenzo Myftari et al.
2 citations
Cardiovascular Drugs and Therapy
Heart Failure Treatment and Management
2.78
article

Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology

Domenico Filomena, Roberto Badagliacca, Rosanna Germanò, Vincenzo Myftari, Nicola Pierucci, Francesca Ferranti, Gennaro Sardella, Silvia Prosperi, Paolo Severino, Gianluca Di Pietro, Marco Valerio Mariani, Lorenzo Colombo, Massimo Mancone, Stefanie Marek‐Iannucci, Claudia Cestiè, Lucia Ilaria Birtolo, Silvia Papa, Carmine Dario Vizza, Andrea D’Amato, Francesco Ciciarello, Giovanna Manzi, Matteo Aulicino, Camilla Segato
article en
2 citations

Abstract

The early in-hospital introduction of SGLT2i reduced the occurrence of the composite CV death/HFH, all-cause death, CV death and HFH in patients with ischemic cardiomyopathy. In the subgroup analysis of patients admitted due to ACS, the introduction of SGLT2i during the index hospitalization resulted in a significant reduction of the composite CV death/HFH, CV death and all-cause death, but not in HFH. The same therapeutic strategy resulted in reduced rate of CV death/HFH in the de novo HF subpopulation.

Cardiovascular Drugs and TherapyVol. 40(2)
Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 10%
Heart Failure Treatment and Management
2.78
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology — Domenico Filomena, Roberto Badagliacca, et al. · Cardiovascular Drugs and Therapy (2025) | TGRS Research Map | TGRS